---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-26-000038"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2026-07-07T21:12:41+00:00"
generated_at: "2026-07-07T21:14:09.565558+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+

## Summary
- Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.
- Acquisition of Naveris closed July 1 for $161.8M cash plus up to $100M earnout based on 2026-2027 revenue milestones.
- Naveris' NavDx test is the only Medicare-covered MRD test for HPV+ head/neck and anal cancers; 130K+ tests reported.
- Naveris generated ~$35M revenue in 2025, more than doubling YoY; ADLT reimbursement rate of $1,800 per test.
- Combined estimated U.S. addressable market exceeds $12B across transplant, specialty oncology, and cell therapy.

## SEC filing metadata
- accession: 0001217234-26-000038
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2026-07-07T21:12:41+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/0001217234-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/cdna-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-26-000038
- JSON: https://secwatch.observer/filing/0001217234-26-000038.json
- Plain text: https://secwatch.observer/filing/0001217234-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.